|Bid||6.80 x 900|
|Ask||6.98 x 900|
|Day's range||6.75 - 6.94|
|52-week range||5.92 - 32.04|
|Beta (5Y monthly)||0.68|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||33.11|
It's hard for any stock to deliver positive gains while the market is falling. Molecular Partners' (NASDAQ: MOLN) shares have skyrocketed more than 40% year to date. On Jan. 10, Molecular Partners and Novartis announced positive results from their Empathy phase 2 study of ensovibep in treating acute COVID-19 patients.
Novartis and Molecular Partners reported positive results for COVID-19 candidate ensovibep.
Regulatory and other pipeline updates from Biogen (BIIB) and AMGN are among a few key highlights from the biotech sector during the past week.